Physician profile
Rachel E Davis
NPI 1972733608
$9,941.98
in general payments reported to CMS, 2019-2025
20 companies · $7,483 in 2025
The $7,483 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $145 · 2021: $222 · 2022: $577 · 2023: $478 · 2024: $359 · 2025: $7,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,588 · Food and Beverage: $1,671 · Travel and Lodging: $60.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,587.50 |
| Food and Beverage | $1,671.23 |
| Travel and Lodging | $60.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,953.11 | 2025 | Tepezza |
| Alcon Vision LLC | $1,134.88 | 2019-2025 | Clareon, Unity, Acrysof Iq Vivity |
| Abbvie INC. | $732.94 | 2022-2025 | Xen Glaucoma Treatment System, Vuity, Lumigan |
| Allergan, INC. | $252.31 | 2019-2021 | |
| Rxsight INC | $146.00 | 2022 | |
| Genentech USA, INC. | $119.74 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $111.16 | 2019 | |
| Dompe US, INC. | $77.54 | 2022-2025 | Oxervate |
| Glaukos Corporation | $74.01 | 2019 | |
| Oyster Point Pharma, INC. | $51.03 | 2024 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $43.28 | 2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Beaver-Visitec International, INC. | $37.34 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $36.85 | 2024 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $35.10 | 2019 | |
| Aerie Pharmaceuticals, INC. | $34.61 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $27.84 | 2020 | |
| Shire North American Group INC | $24.23 | 2019 | |
| Bausch & Lomb Americas INC. | $17.95 | 2025 | Stellaris |
| Omeros Corporation | $16.92 | 2021 | |
| Astellas Pharma US INC | $15.14 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.